alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial - PubMed (original) (raw)
Clinical Trial
alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial
G Barbagallo Sangiorgi et al. Ann N Y Acad Sci. 1994.
Abstract
The clinical efficacy and the tolerability of alpha-glycerophosphocholine (alpha-GPC), a drug able to provide high levels of choline for the nervous cells of the brain and to protect their cell walls, have been tested in a clinical open multicenter trial on 2044 patients suffering from recent stroke or transient ischemic attacks. alpha-GPC was administered after the attack at the daily dose of 1000 mg im for 28 days and orally at the dose of 400 mg tid during the following 5 months after the first phase. The evaluation of the efficacy on the psychic recovery was done by the Mathew Scale (MS) during the period of im drug administration, and using the Mini Mental State Test (MMST), the Crichton Rating Scale (CRS), and the Global Deterioration Scale (GDS) during the following period of oral administration. The MS mean increased 15.9 points in 28 days in a statistically significant way (p < 0.001) from 58.7 to 74.6. At the end of the 5 month oral administration, the CRS mean significantly decreased 4.3 points, from 20.2 to 15.9 (p < 0.001); the MMST mean significantly increased (p < 0.001) from 21 to 24.3 at the end of the trial, reaching the "normality" score at the 3rd month assessment. The GDS score at the end of the trial corresponded to "no cognitive decline" or "forgetfulness" in 71% of the patients. Adverse events were complained of by 44 patients (2.14%); in 14 (0.7%) the investigator preferred to discontinue therapy. The most frequent complaints were heartburn (0.7%), nausea-vomit (0.5%), insomnia-excitation (0.4%), and headache (0.2%). The trial confirms the therapeutic role of alpha-GPC on the cognitive recovery of patients with acute stroke or TIA, and the low percentage of adverse events confirms its excellent tolerability.
Similar articles
- A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia.
Di Perri R, Coppola G, Ambrosio LA, Grasso A, Puca FM, Rizzo M. Di Perri R, et al. J Int Med Res. 1991 Jul-Aug;19(4):330-41. doi: 10.1177/030006059101900406. J Int Med Res. 1991. PMID: 1916007 Clinical Trial. - Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.
Parnetti L, Amenta F, Gallai V. Parnetti L, et al. Mech Ageing Dev. 2001 Nov;122(16):2041-55. doi: 10.1016/s0047-6374(01)00312-8. Mech Ageing Dev. 2001. PMID: 11589921 - Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.
Alvarez-Sabín J, Ortega G, Jacas C, Santamarina E, Maisterra O, Ribo M, Molina C, Quintana M, Román GC. Alvarez-Sabín J, et al. Cerebrovasc Dis. 2013;35(2):146-54. doi: 10.1159/000346602. Epub 2013 Feb 7. Cerebrovasc Dis. 2013. PMID: 23406981 Clinical Trial. - Donepezil for vascular cognitive impairment.
Malouf R, Birks J. Malouf R, et al. Cochrane Database Syst Rev. 2004;(1):CD004395. doi: 10.1002/14651858.CD004395.pub2. Cochrane Database Syst Rev. 2004. PMID: 14974068 Review. - Rivastigmine for vascular cognitive impairment.
Birks J, McGuinness B, Craig D. Birks J, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD004744. doi: 10.1002/14651858.CD004744.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728651 Review.
Cited by
- Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial.
Jeon J, Lee SY, Lee S, Han C, Park GD, Kim SJ, Chang JG, Kim WJ. Jeon J, et al. BMC Geriatr. 2024 Sep 19;24(1):774. doi: 10.1186/s12877-024-05366-7. BMC Geriatr. 2024. PMID: 39300341 Free PMC article. Clinical Trial. - Choline-Containing Phospholipids in Stroke Treatment: A Systematic Review and Meta-Analysis.
Sagaro GG, Amenta F. Sagaro GG, et al. J Clin Med. 2023 Apr 14;12(8):2875. doi: 10.3390/jcm12082875. J Clin Med. 2023. PMID: 37109211 Free PMC article. Review. - Choline supplements: An update.
Kansakar U, Trimarco V, Mone P, Varzideh F, Lombardi A, Santulli G. Kansakar U, et al. Front Endocrinol (Lausanne). 2023 Mar 7;14:1148166. doi: 10.3389/fendo.2023.1148166. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36950691 Free PMC article. Review. - Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Sagaro GG, Traini E, Amenta F. Sagaro GG, et al. J Alzheimers Dis. 2023;92(1):59-70. doi: 10.3233/JAD-221189. J Alzheimers Dis. 2023. PMID: 36683513 Free PMC article. - A Nutraceutical Formula Is Effective in Raising the Circulating Vitamin and Mineral Levels in Healthy Subjects: A Randomized Trial.
Nenseth HZ, Sahu A, Saatcioglu F, Osguthorpe S. Nenseth HZ, et al. Front Nutr. 2021 Sep 1;8:703394. doi: 10.3389/fnut.2021.703394. eCollection 2021. Front Nutr. 2021. PMID: 34540877 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources